SEARCH

SEARCH BY CITATION

References

  • Arbouzova, N.I. & Zeidler, M.P. (2006) JAK/STAT signalling in Drosophila: insights into conserved regulatory and cellular functions. Development, 133, 26052616.
  • Bach, E.A., Vincent, S., Zeidler, M.P. & Perrimon, N. (2003) A sensitized genetic screen to identify novel regulators and components of the Drosophila janus kinase/signal transducer and activator of transcription pathway. Genetics, 165, 11491166.
  • Baeg, G.H., Zhou, R. & Perrimon, N. (2005) Genome-wide RNAi analysis of JAK/STAT signaling components in Drosophila. Genes & Development, 19, 18611870.
  • Battle, T.E. & Frank, D.A. (2002) The role of STATs in apoptosis. Current Molecular Medicine, 2, 381392.
  • Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. & Cancer Genome Project. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 10541061.
  • Changelian, P.S., Flanagan, M.E., Ball, D.J., Kent, C.R., Magnuson, K.S., Martin, W.H., Rizzuti, B.J., Sawyer, P.S., Perry, B.D., Brissette, W.H., McCurdy, S.P., Kudlacz, E.M., Conklyn, M.J., Elliott, E.A., Koslov, E.R., Fisher, M.B., Strelevitz, T.J., Yoon, K., Whipple, D.A., Sun, J., Munchhof, M.J., Doty, J.L., Casavant, J.M., Blumenkopf, T.A., Hines, M., Brown, M.F., Lillie, B.M., Subramanyam, C., Shang-Poa, C., Milici, A.J., Beckius, G.E., Moyer, J.D., Su, C., Woodworth, T.G., Gaweco, A.S., Beals, C.R., Littman, B.H., Fisher, D.A., Smith, J.F., Zagouras, P., Magna, H.A., Saltarelli, M.J., Johnson, K.S., Nelms, L.F., Des Etages, S.G., Hayes, L.S., Kawabata, T.T., Finco-Kent, D., Baker, D.L., Larson, M., Si, M.S., Paniagua, R., Higgins, J., Holm, B., Reitz, B., Zhou, Y.J., Morris, R.E., O’Shea, J.J. & Borie, D.C. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science, 302, 875878.
  • Chilton, B.S. & Hewetson, A. (2005) Prolactin and growth hormone signaling. Current Topics in Developmental Biology, 68, 123.
  • Darnell, J.E. (2005) Validating Stat3 in cancer therapy. Nature Medicine, 11, 595596.
  • Decker, P., Isenberg, D. & Muller, S. (2000) Inhibition of caspase-3-mediated poly(ADP-ribose) polymerase (PARP) apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis. The Journal of Biological Chemistry, 275, 90439046.
  • Diaz, N., Minton, S., Cox, C., Bowman, T., Gritsko, T., Garcia, R., Eweis, I., Wloch, M., Livingston, S., Seijo, E., Cantor, A., Lee, J.H., Beam, C.A., Sullivan, D., Jove, R. & Muro-Cacho, C.A. (2006) Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clinical Cancer Research, 12, 2028.
  • Duke, J.A. (2000) Handbook of Edible Weeds: Herbal Reference Library. Taylor & Francis LLC, CRC Press, Boca Raton, FL, USA, 144145.
  • Eisenbrand, G., Hippe, F., Jakobs, S. & Muehlbeyer, S. (2004) Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. Journal of Cancer Research and Clinical Oncology, 130, 627635.
  • Epling-Burnette, P.K., Liu, J.H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.M., Yang-Yen, H.F., Karras, J., Jove, R. & Loughran, Jr, T.P. (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. The Journal of Clinical Investigation, 107, 351362.
  • Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F., Martinelli, S., Fragale, A., Sanchez, M., Tavolaro, S., Messina, M., Cazzaniga, G., Camera, A., Pizzolo, G., Tornesello, A., Vignetti, M., Battistini, A., Cavé, H., Gelb, B.D., Renauld, J.C., Biondi, A., Constantinescu, S.N., Foà, R. & Tartaglia, M. (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. The Journal of Experimental Medicine, 205, 751758.
  • Grover, J.K. & Yadav, S.P. (2004) Pharmacological actions and potential uses of Momordica charantia: a review. Journal of Ethnopharmacology, 93, 123132.
  • Hou, S.X., Zheng, Z., Chen, X. & Perrimon, N. (2002) The Jak/STAT pathway in model organisms: emerging roles in cell movement. Developmental Cell, 3, 765778.
  • James, C., Ugo, V., Le Couédic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Natrure, 434, 11441148.
  • Jones, A.V., Chase, A., Silver, R.T., Oscier, D., Zoi, K., Wang, Y.L., Cario, H., Pahl, H.L., Collins, A., Reiter, A., Grand, F. & Cross, N.C. (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nature Genetics, 41, 446449.
  • Kang, K., Park, S., Kim, Y.S., Lee, S. & Back, K. (2009) Biosynthesis and biotechnological production of serotonin derivatives. Applied Microbiology and Biotechnology, 83, 2734.
  • Kawashima, S., Hayashi, M., Takii, T., Kimura, H., Zhang, H.L., Nagatsu, A., Sakakibara, J., Murata, K., Oomoto, Y. & Onozaki, K. (1998) Serotonin derivative, N-(p-coumaroyl) serotonin, inhibits the production of TNF-alpha, IL-1alpha, IL-1beta, and IL-6 by endotoxin-stimulated human blood monocytes. Journal of Interferon & Cytokine Research, 18, 423428.
  • Kilpivaara, O., Mukherjee, S., Schram, A.M., Wadleigh, M., Mullally, A., Ebert, B.L., Bass, A., Marubayashi, S., Heguy, A., Garcia-Manero, G., Kantarjian, H., Offit, K., Stone, R.M., Gilliland, D.G., Klein, R.J. & Levine, R.L. (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nature Genetics, 41, 455459.
  • Kim, B.H., Yin, C.H., Guo, Q., Bach, E.A., Lee, H., Sandoval, C., Jayabose, S., Ulaczyk-Lesanko, A., Hall, D.G. & Baeg, G.H. (2008) A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells. Molecular Cancer Therapeutics, 7, 26722680.
  • Kirken, R.A., Rui, H., Malabarba, M.G. & Farrar, W.L. (1994) Identification of interleukin-2 receptor-associated tyrosine kinase p116 as novel leukocyte-specific Janus kinase. The Journal of Biological Chemistry, 269, 1913619141.
  • Kiyoi, H., Yamaji, S., Kojima, S. & Naoe, T. (2007) JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia, 21, 574576.
  • Klampfer, L. (2006) Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Current Cancer Drug Targets, 6, 107121.
  • Kota, J., Caceres, N. & Constantinescu, S.N. (2008) Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia, 22, 18281840.
  • Levine, R.L. (2009) Janus kinase mutations. Seminars in Oncology, 36, S6S11.
  • Levine, R.L., Loriaux, M., Huntly, B.J., Loh, M.L., Beran, M., Stoffregen, E., Berger, R., Clark, J.J., Willis, S.G., Nguyen, K.T., Flores, N.J., Estey, E., Gattermann, N., Armstrong, S., Look, A.T., Griffin, J.D., Bernard, O.A., Heinrich, M.C., Gilliland, D.G., Druker, B. & Deininger, M.W. (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 106, 33773379.
  • Levy, D.E. & Darnell, Jr, J.E. (2002) Stats: transcriptional control and biological impact. Nature Reviews. Molecular Cell Biology, 3, 651662.
  • Mahboubi, K., Li, F., Plescia, J., Kirkiles-Smith, N.C., Mesri, M., Du, Y., Carroll, J.M., Elias, J.A., Altieri, D.C. & Pober, J.S. (2001) Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Laboratory Investigation, 81, 327334.
  • Malinge, S., Ragu, C., Della-Valle, V., Pisani, D., Constantinescu, S.N., Perez, C., Villeval, J.L., Reinhardt, D., Landman-Parker, J., Michaux, L., Dastugue, N., Baruchel, A., Vainchenker, W., Bourquin, J.P., Penard-Lacronique, V. & Bernard, O.A. (2008) Activating mutations in human acute megakaryoblastic leukemia. Blood, 112, 42204226.
  • Meraz, M.A., White, J.M., Sheehan, K.C., Bach, E.A., Rodig, S.J., Dighe, A.S., Kaplan, D.H., Riley, J.K., Greenlund, A.C., Campbell, D., Carver-Moore, K., DuBois, R.N., Clark, R., Aguet, M. & Schreiber, R.D. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell, 84, 431442.
  • Mullighan, C.G., Zhang, J., Harvey, R.C., Collins-Underwood, J.R., Schulman, B.A., Phillips, L.A., Tasian, S.K., Loh, M.L., Su, X., Liu, W., Devidas, M., Atlas, S.R., Chen, I.M., Clifford, R.J., Gerhard, D.S., Carroll, W.L., Reaman, G.H., Smith, M., Downing, J.R., Hunger, S.P. & Willman, C.L. (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 106, 94149418.
  • Neilson, L.M., Zhu, J., Xie, J., Malabarba, M.G., Sakamoto, K., Wagner, K.U., Kirken, R.A. & Rui, H. (2007) Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Molecular Endocrinology, 21, 22182232.
  • Neubauer, H., Cumano, A., Müller, M., Wu, H., Huffstadt, U. & Pfeffer, K. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell, 93, 397409.
  • Niwa, T., Etoh, H., Shimizu, A. & Shimizu, Y. (2000) Cis-N-(p-Coumaroyl)serotonin from Konnyaku, Amorphophallus konjac K. Koch. Bioscience, Biotechnology, and Biochemistry, 64, 22692271.
  • Nosaka, T., Van Deursen, J.M., Tripp, R.A., Thierfelder, W.E., Witthuhn, B.A., McMickle, A.P., Doherty, P.C., Grosveld, G.C. & Ihle, J.N. (1995) Defective lymphoid development in mice lacking Jak3. Science, 270, 800802.
  • Nybakken, K., Vokes, S.A., Lin, T.Y., McMahon, A.P. & Perrimon, N. (2005) A genome-wide RNA interference screen in Drosophila melanogater cells for new components of the Hh signaling pathway. Nature Genetics, 37, 13231332.
  • O’Shea, J.J., Pesu, M., Borie, D.C. & Changelian, P.S. (2004) A new modality for immunosuppression: targeting the JAK/STAT pathway. Nature Reviews. Drug Discovery, 3, 555564.
  • Olcaydu, D., Harutyunyan, A., Jäger, R., Berg, T., Gisslinger, B., Pabinger, I., Gisslinger, H. & Kralovics, R. (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nature Genetics, 41, 450454.
  • Park, J.B. & Schoene, N. (2002) Synthesis and characterization of N-coumaroyltyramine as a potent phytochemical which arrests human transformed cells via inhibiting protein tyrosine kinases. Biochemical and Biophysical Research Communications, 292, 11041110.
  • Park, S.Y., Saijo, K., Takahashi, T., Osawa, M., Arase, H., Hirayama, N., Miyake, K., Nakauchi, H., Shirasawa, T. & Saito, T. (1995) Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity, 3, 771782.
  • Parsons, S.J. & Parsons, J.T. (2004) Src family kinases, key regulators of signal transduction. Oncogene, 23, 79067909.
  • Pesu, M., Candotti, F., Husa, M., Hofmann, S.R., Notarangelo, L.D. & O’Shea, J.J. (2005) Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunological Reviews, 203, 127142.
  • Pesu, M., Laurence, A., Kishore, N., Zwillich, S.H., Chan, G. & O’Shea, J.J. (2008) Therapeutic targeting of Janus kinases. Immunological Reviews, 223, 132142.
  • Reiterer, G. & Yen, A. (2006) Inhibition of the janus kinase family increases extracellular signal-regulated kinase 1/2 phosphorylation and causes endoreduplication. Cancer Research, 66, 90839089.
  • Roh, J.S., Han, J.Y., Kim, J.H. & Hwang, J.K. (2004) Inhibitory effects of active compounds isolated from safflower (Carthamus tinctorius L.) seeds for melanogenesis. Biological & Pharmaceutical Bulletin, 27, 19761978.
  • Rui, H., Kirken, R.A. & Farrar, W.L. (1994) Activation of receptor-associated tyrosine kinase JAK2 by prolactin. The Journal of Biological Chemistry, 269, 53645368.
  • Sato, T., Toki, T., Kanezaki, R., Xu, G., Terui, K., Kanegane, H., Miura, M., Adachi, S., Migita, M., Morinaga, S., Nakano, T., Endo, M., Kojima, S., Kiyoi, H., Mano, H. & Ito, E. (2008) Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. British Journal of Haematology, 141, 681688.
  • Schindler, C., Shuai, K., Prezioso, V.R. & Darnell, Jr, J.E. (1992) Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science, 257, 809813.
  • Schindler, C., Levy, D.E. & Decker, T. (2007) JAK-STAT signaling: from interferons to cytokines. The Journal of Biological Chemistry, 282, 2005920063.
  • Shuai, K., Schindler, C., Prezioso, V.R. & Darnell, Jr, J.E. (1992) Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science, 285, 18081812.
  • Shuai, K., Stark, G.R., Kerr, I.M. & Darnell, Jr, J.E. (1993a) A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science, 261, 17441746.
  • Shuai, K., Ziemiecki, A., Wilks, A.F., Harpur, A.G., Sadowski, H.B., Gilman, M.Z. & Darnell, Jr, J.E. (1993b) Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature, 366, 580583.
  • Shuai, K., Horvath, C.M., Huang, L.H., Qureshi, S.A., Cowburn, D. & Darnell, Jr, J.E. (1994) Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell, 76, 821828.
  • Steelman, L.S., Pohnert, S.C., Shelton, J.G., Franklin, R.A., Bertrand, F.E. & McCubrey, J.A. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 18, 189218.
  • Stepkowski, S.M., Erwin-Cohen, R.A., Behbod, F., Wang, M.E., Qu, X., Tejpal, N., Nagy, Z.S., Kahan, B.D. & Kirken, R.A. (2002) Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood, 99, 680689.
  • Stepkowski, S.M., Kao, J., Wang, M.E., Tejpal, N., Podder, H., Furian, L., Dimmock, J., Jha, A., Das, U., Kahan, B.D. & Kirken, R.A. (2005) The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. Journal of Immunology, 175, 42364246.
  • Stickel, F. & Schuppan, D. (2007) Herbal medicine in the treatment of liver diseases. Digestive and Liver Disease, 39, 293304.
  • Sudbeck, E.A., Liu, X.P., Narla, R.K., Mahajan, S., Ghosh, S., Mao, C. & Uckun, F.M. (1999) Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clinical Cancer Research, 5, 15691582.
  • Takii, T., Hayashi, M., Hiroma, H., Chiba, T., Kawashima, S., Zhang, H.L., Nagatsu, A., Sakakibara, J. & Onozaki, K. (1999) Serotonin derivative, N-(p-Coumaroyl)serotonin, isolated from safflower (Carthamus tinctorius L.) oil cake augments the proliferation of normal human and mouse fibroblasts in synergy with basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). Journal of Biochemistry, 125, 910915.
  • Thomis, D.C., Gurniak, C.B., Tivol, E., Sharpe, A.H. & Berg, L.J. (1995) Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science, 270, 794797.
  • Velazquez, L., Fellous, M., Stark, G.R. & Pellegrini, S. (1992) A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell, 70, 313322.
  • Walters, D.K., Mercher, T., Gu, T.L., O’Hare, T., Tyner, J.W., Loriaux, M., Goss, V.L., Lee, K.A., Eide, C.A., Wong, M.J., Stoffregen, E.P., McGreevey, L., Nardone, J., Moore, S.A., Crispino, J., Boggon, T.J., Heinrich, M.C., Deininger, M.W., Polakiewicz, R.D., Gilliland, D.G. & Druker, B.J. (2006) Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell, 10, 6575.
  • Watling, D., Guschin, D., Müller, M., Silvennoinen, O., Witthuhn, B.A., Quelle, F.W., Rogers, N.C., Schindler, C., Stark, G.R., Ihle, J.N. & Kerr, I.M. (1993) Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature, 366, 166170.
  • Yu, H. & Jove, R. (2004) The STATs of cancer – new molecular targets come of age. Nature reviews. Cancer, 4, 97105.
  • Zeidler, M.P., Bach, E.A. & Perrimon, N. (2000) The roles of the Drosophila JAK/STAT pathway. Oncogene, 19, 25982606.
  • Zhou, L., Zuo, Z. & Chow, M.S. (2005) Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. Journal of Clinical Pharmacology, 45, 13451359.